Abstract:Abstract Deubiquitinases (DUBs) play important roles in various human cancers and targeting DUBs is considered as a novel anticancer therapeutic strategy. Overexpression of ubiquitin specific protease 7 and 22 (USP7 and USP22) are associated with malignancy, therapy resistance, and poor prognosis in many cancers. Although both DUBs are involved in the regulation of similar genes and signaling pathways, such as histone H2B monoubiquitination (H2Bub1), c-Myc, FOXP3, and P53, the interdependence of USP22 and USP7 expression has never been described. In the study, we found targeting USP7 via either siRNA-mediated knockdown or pharmaceutical inhibitors dramatically upregulates USP22 in cancer cells. Mechanistically, the elevated USP22 occurs through a transcriptional pathway, possibly due to desuppression of the transcriptional activity of SP1 via promoting its degradation upon USP7 inhibition. Importantly, the elevated USP22 leads to significant activation of downstream signal pathways including H2Bub1 and c-Myc, which may potentially enhance cancer malignancy and counteract the anticancer efficacy of USP7 inhibition. Importantly, targeting USP7 further suppresses the in vitro proliferation of USP22-knockout (USP22-Ko) A549 and H1299 lung cancer cells and induces a stronger activation of P53 tumor suppressor signaling pathway. In addition, USP22-Ko cancer cells are more sensitive to a combination of cisplatin and USP7. USP7 inhibitor treatment further suppresses the in vivo angiogenesis and growth and induced more apoptosis in USP22-Ko cancer xenografts. Taken together, our findings demonstrate that USP7 inhibition can dramatically upregulate USP22 in cancer cells; and targeting USP7 and USP22 may represent a more effective approach for targeted cancer therapy, which warrants further study. Citation Format: Keqiang Zhang, Ting Sun, Wendong Li, Jun Wu, Dan Raz. Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3939.

USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A.

Ubiquitin-specific peptidase 22 in cancer

Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma

Abstract 3939: Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells

USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

Targeting Ubiquitin-Specific Protease 22 Suppresses Growth and Metastasis of Anaplastic Thyroid Carcinoma.

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

Deubiquitination of the Repressor E2F6 by USP22 Facilitates AKT Activation and Tumor Growth in Hepatocellular Carcinoma

Down-regulation of USP22 reduces cell stemness and enhances the sensitivity of pancreatic cancer cells to cisplatin by inactivating the Wnt/β-catenin pathway

A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis

Dysregulation and oncogenic activities of ubiquitin specific peptidase 2a in the pathogenesis of hepatocellular carcinoma

Ubiquitin‐specific Protease 22 Promotes Tumorigenesis and Progression by an FKBP12/mTORC1/autophagy Positive Feedback Loop in Hepatocellular Carcinoma

Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics

USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target

USP10 as a Potential Therapeutic Target in Human Cancers

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1

Prognostic Significance of USP22 As an Oncogene in Papillary Thyroid Carcinoma

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants